1. Home
  2. LITB vs VERU Comparison

LITB vs VERU Comparison

Compare LITB & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LightInTheBox Holding Co. Ltd.

LITB

LightInTheBox Holding Co. Ltd.

BUY

Current Price

$2.26

Market Cap

47.2M

ML Signal

BUY

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.35

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITB
VERU
Founded
2007
1971
Country
Singapore
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.2M
40.9M
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
LITB
VERU
Price
$2.26
$2.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
11.8K
51.3K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$0.36
52 Week High
$4.17
$4.59

Technical Indicators

Market Signals
Indicator
LITB
VERU
Relative Strength Index (RSI) 45.07 48.91
Support Level $1.84 $2.13
Resistance Level $2.25 $2.70
Average True Range (ATR) 0.22 0.12
MACD 0.01 0.03
Stochastic Oscillator 57.58 53.70

Price Performance

Historical Comparison
LITB
VERU

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: